Form 10-Q · Quarterly report
Bristol Myers Squibb 10-Q, filed Jul 30, 2026
- Filed
- CIK
- 0000014272
- Accession no.
- 0000014272-26-000020
Summary
Bristol Myers Squibb reported second-quarter 2026 total revenues of $12.973 billion, up 6%, and GAAP diluted EPS of $1.62, while advancing regulatory filings for iberdomide and mezigdomide in relapsed/refractory multiple myeloma and receiving new approvals for Sotyktu and Opdivo.
Key points
- Bristol Myers Squibb reported second-quarter 2026 total revenues of $12.973 billion, up 6% from a year earlier, and GAAP diluted EPS of $1.62 versus $0.64.
- The company said the FDA accepted NDAs for iberdomide and mezigdomide in relapsed/refractory multiple myeloma, with PDUFA dates of August 17, 2026, and May 13, 2027.
- In May 2026, Bristol Myers Squibb entered global strategic collaboration and license agreements with Hengrui for 13 early-stage oncology, hematology, and immunology assets.
- The company expects annual cost savings of approximately $2.0 billion by the end of 2027 under its strategic productivity initiative.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
From the filing
Item 2. MANAGEMENT’S DISCUSSION EXECUTIVE SUMMARY Our principal strategy is to combine the resources, scale and capability of a large pharmaceutical company with the speed, agility and focus on innovation typically found in the biotech industry. Our focus as a biopharmaceutical company is on discovering, developing and delivering transformational medicines for patients facing serious diseases in areas where we believe that we have an opportunity to make a meaningful difference: oncology, hematology, immunology, cardiovascular, neuroscience and other areas where we can also create long-term value. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.